Literature DB >> 21754963

Aripiprazole-induced seizure: a second case report.

Che-Lin Yueh1, Sung-Lin Yu, Hsiao-Min Chen, Bo-Jian Wu, Wen-Ching Chen.   

Abstract

Aripiprazole has been recognised as a third generation antipsychotic and is considered to be distinguished from typical and atypical antipsychotics. In clinical trials, researchers did not mention the risk of aripiprazole-induced seizure, but during a literature review a case report was found that discussed this potential side effect. The present report concerns a 54-year-old man with chronic schizophrenia who developed a witnessed grand mal seizure after he had abruptly discontinued clozapine and benzodiazepam (BZD) treatment and concurrently reinitiated aripiprazole treatment as the result of an involuntary clinical error. The possible causes were explored, including clozapine-induced or withdrawal seizure, BZD withdrawal syndrome, psychogenic non-epileptic seizure, hyponatraemia, brain tumour and major physical illness, but none of the hypotheses can explain the seizure observed in this case. This second case is presented to corroborate a previous finding and emphasise the possibility of aripiprazole-induced seizure.

Entities:  

Year:  2009        PMID: 21754963      PMCID: PMC3028097          DOI: 10.1136/bcr.03.2009.1693

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

Review 1.  Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

Authors:  M J Millan
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

2.  Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.

Authors:  S M Stahl
Journal:  J Clin Psychiatry       Date:  2001-12       Impact factor: 4.384

Review 3.  Clozapine. A novel antipsychotic agent.

Authors:  R J Baldessarini; F R Frankenburg
Journal:  N Engl J Med       Date:  1991-03-14       Impact factor: 91.245

4.  Workplace violence on workers caring for long-term institutionalized schizophrenic patients in Taiwan.

Authors:  Wen-Ching Chen; Jung-Der Wang; Chih-Yin Lew-Ting; Hsien-Jane Chiu; Yi-Ping Lin
Journal:  J Occup Health       Date:  2007-07       Impact factor: 2.708

5.  Biological perspectives. Aripiprazole: a third generation of antipsychotics begins?

Authors:  Norman L Keltner; Vicki Johnson
Journal:  Perspect Psychiatr Care       Date:  2002 Oct-Dec       Impact factor: 2.186

6.  Adverse drug reactions with clozapine and simultaneous application of benzodiazepines.

Authors:  N Sassim; R Grohmann
Journal:  Pharmacopsychiatry       Date:  1988-11       Impact factor: 5.788

7.  Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.

Authors:  G Chouinard
Journal:  Schizophr Res       Date:  1991 Jul-Aug       Impact factor: 4.939

8.  Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Authors:  Stephen R Marder; Robert D McQuade; Elyse Stock; Stephen Kaplita; Ronald Marcus; Allan Z Safferman; Anutosh Saha; Mirza Ali; Taro Iwamoto
Journal:  Schizophr Res       Date:  2003-06-01       Impact factor: 4.939

Review 9.  Update on the clinical efficacy and side effects of clozapine.

Authors:  A Safferman; J A Lieberman; J M Kane; S Szymanski; B Kinon
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

10.  Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.

Authors:  Siegfried Kasper; Mark N Lerman; Robert D McQuade; Anutosh Saha; William H Carson; Mirza Ali; Donald Archibald; Gary Ingenito; Ronald Marcus; Teresa Pigott
Journal:  Int J Neuropsychopharmacol       Date:  2003-12       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.